2025 H2 -tulosraportti
68 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 284 | - | - | ||
| 10 000 | - | - | ||
| 4 230 | - | - | ||
| 740 | - | - | ||
| 13 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenPossible reason for missing price target ?? 1. "Binary Risk" – All or nothing In the financial world, this is called binary risk. Either the technology works (production of alpha-emitters from thorium without a reactor), or it does not work on an industrial scale. If the analyst sets a price target of 50 kroner and the technology fails in the test phase now in Q3, they look unprofessional. If they set a price target of 5 kroner (near today's price) and Thor Medical actually becomes the global monopolist for a critical cancer medicine component, they have missed "the industrial adventure of the decade". Most therefore choose to say nothing rather than taking the risk of failing completely. 2. The lack of comparable companies (Peer Group) Analysts love to compare. "If company A is worth 10x revenues, company B should be the same." The problem with Thor Medical is that they do something no one else does in exactly the same way. They produce radioactive isotopes in an environmentally friendly way from natural thorium. Since there is no "off-the-shelf model" to value such a unique process, their calculations become just guesswork. Then they rather sit still and wait for actual revenue figures. 3. The fear of "Hype" vs. Realities The history on the Oslo Stock Exchange is full of companies that promised industrial adventures (think of hydrogen, plastic recycling or biotech), but where the path to profitability became much longer and more expensive than planned. Insiders are buying: As we saw in March 2026, both CEO and CFO have used their own money to increase their exposure in the stock. This is a strong signal that analysts notice, but they rarely dare to use it as the sole basis for a price target before they see the first sales contracts rolling in. Conclusion You are right that they are afraid to fail. For an analyst, it is often safer to "arrive late to the party" (upgrade the stock when the price has already doubled on good news) than to be the first to cry "wolf" and be wrong.
·1 t sittenThis was a very clear description of the situation and most of us here benefit from being updated (reminded) of this. I'm not thinking much about the price now, but will follow much more closely when autumn and winter come. It will be incredibly exciting!
·14 t sittenCircio the trader who dumped 3.6 million shares when the stock went -11% before the weekend. New blood in.·5 t sitten · MuokattuA trader who has held 4,5 mnok shares at one point. In and out of both Circio and Trmed, but seems to have made a killing with some mill shares from approx. price 1 to 5,5.·2 t sitten · MuokattuHe was top 8 with 4,3 mill shares that day you still had 14,5 mill shares.
·1 päivä sitten · MuokattuWhat could be the next share price trigger? I am a bit skeptical whether production start can be sufficient for a share price increase. Investors will then start focusing on earnings and balancing these against market expectations. I.e., there will likely be a wait-and-see attitude until we see some quarterly reports. But then I also believe that the clock towards an acquisition will start ticking when deliveries are sent out in rapidly increasing volume and there are no problems. Tor currently has a strategic importance for the market. I believe this explains some of the current trading bandwidth.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
68 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenPossible reason for missing price target ?? 1. "Binary Risk" – All or nothing In the financial world, this is called binary risk. Either the technology works (production of alpha-emitters from thorium without a reactor), or it does not work on an industrial scale. If the analyst sets a price target of 50 kroner and the technology fails in the test phase now in Q3, they look unprofessional. If they set a price target of 5 kroner (near today's price) and Thor Medical actually becomes the global monopolist for a critical cancer medicine component, they have missed "the industrial adventure of the decade". Most therefore choose to say nothing rather than taking the risk of failing completely. 2. The lack of comparable companies (Peer Group) Analysts love to compare. "If company A is worth 10x revenues, company B should be the same." The problem with Thor Medical is that they do something no one else does in exactly the same way. They produce radioactive isotopes in an environmentally friendly way from natural thorium. Since there is no "off-the-shelf model" to value such a unique process, their calculations become just guesswork. Then they rather sit still and wait for actual revenue figures. 3. The fear of "Hype" vs. Realities The history on the Oslo Stock Exchange is full of companies that promised industrial adventures (think of hydrogen, plastic recycling or biotech), but where the path to profitability became much longer and more expensive than planned. Insiders are buying: As we saw in March 2026, both CEO and CFO have used their own money to increase their exposure in the stock. This is a strong signal that analysts notice, but they rarely dare to use it as the sole basis for a price target before they see the first sales contracts rolling in. Conclusion You are right that they are afraid to fail. For an analyst, it is often safer to "arrive late to the party" (upgrade the stock when the price has already doubled on good news) than to be the first to cry "wolf" and be wrong.·1 t sittenThis was a very clear description of the situation and most of us here benefit from being updated (reminded) of this. I'm not thinking much about the price now, but will follow much more closely when autumn and winter come. It will be incredibly exciting!
- ·14 t sittenCircio the trader who dumped 3.6 million shares when the stock went -11% before the weekend. New blood in.·5 t sitten · MuokattuA trader who has held 4,5 mnok shares at one point. In and out of both Circio and Trmed, but seems to have made a killing with some mill shares from approx. price 1 to 5,5.·2 t sitten · MuokattuHe was top 8 with 4,3 mill shares that day you still had 14,5 mill shares.
- ·1 päivä sitten · MuokattuWhat could be the next share price trigger? I am a bit skeptical whether production start can be sufficient for a share price increase. Investors will then start focusing on earnings and balancing these against market expectations. I.e., there will likely be a wait-and-see attitude until we see some quarterly reports. But then I also believe that the clock towards an acquisition will start ticking when deliveries are sent out in rapidly increasing volume and there are no problems. Tor currently has a strategic importance for the market. I believe this explains some of the current trading bandwidth.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 284 | - | - | ||
| 10 000 | - | - | ||
| 4 230 | - | - | ||
| 740 | - | - | ||
| 13 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
68 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenPossible reason for missing price target ?? 1. "Binary Risk" – All or nothing In the financial world, this is called binary risk. Either the technology works (production of alpha-emitters from thorium without a reactor), or it does not work on an industrial scale. If the analyst sets a price target of 50 kroner and the technology fails in the test phase now in Q3, they look unprofessional. If they set a price target of 5 kroner (near today's price) and Thor Medical actually becomes the global monopolist for a critical cancer medicine component, they have missed "the industrial adventure of the decade". Most therefore choose to say nothing rather than taking the risk of failing completely. 2. The lack of comparable companies (Peer Group) Analysts love to compare. "If company A is worth 10x revenues, company B should be the same." The problem with Thor Medical is that they do something no one else does in exactly the same way. They produce radioactive isotopes in an environmentally friendly way from natural thorium. Since there is no "off-the-shelf model" to value such a unique process, their calculations become just guesswork. Then they rather sit still and wait for actual revenue figures. 3. The fear of "Hype" vs. Realities The history on the Oslo Stock Exchange is full of companies that promised industrial adventures (think of hydrogen, plastic recycling or biotech), but where the path to profitability became much longer and more expensive than planned. Insiders are buying: As we saw in March 2026, both CEO and CFO have used their own money to increase their exposure in the stock. This is a strong signal that analysts notice, but they rarely dare to use it as the sole basis for a price target before they see the first sales contracts rolling in. Conclusion You are right that they are afraid to fail. For an analyst, it is often safer to "arrive late to the party" (upgrade the stock when the price has already doubled on good news) than to be the first to cry "wolf" and be wrong.·1 t sittenThis was a very clear description of the situation and most of us here benefit from being updated (reminded) of this. I'm not thinking much about the price now, but will follow much more closely when autumn and winter come. It will be incredibly exciting!
- ·14 t sittenCircio the trader who dumped 3.6 million shares when the stock went -11% before the weekend. New blood in.·5 t sitten · MuokattuA trader who has held 4,5 mnok shares at one point. In and out of both Circio and Trmed, but seems to have made a killing with some mill shares from approx. price 1 to 5,5.·2 t sitten · MuokattuHe was top 8 with 4,3 mill shares that day you still had 14,5 mill shares.
- ·1 päivä sitten · MuokattuWhat could be the next share price trigger? I am a bit skeptical whether production start can be sufficient for a share price increase. Investors will then start focusing on earnings and balancing these against market expectations. I.e., there will likely be a wait-and-see attitude until we see some quarterly reports. But then I also believe that the clock towards an acquisition will start ticking when deliveries are sent out in rapidly increasing volume and there are no problems. Tor currently has a strategic importance for the market. I believe this explains some of the current trading bandwidth.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 284 | - | - | ||
| 10 000 | - | - | ||
| 4 230 | - | - | ||
| 740 | - | - | ||
| 13 | - | - |
Välittäjätilasto
Dataa ei löytynyt